Evidence map›Paper›PMID 21228626›Full record

ReviewCancer biology & therapy2011

Autophagy as a therapeutic target in cancer.

Ning Chen, Vassiliki Karantza

Abstract readReview
In one paragraph

Review in Cancer biology & therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 156 papers.

0numbers the graph read from it
0cells of the map it votes in
156citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

156 citing papers in PubMed.

  1. Autophagy in Melanoma: Molecular Mechanisms and Therapeutic Perspectives.International journal of molecular sciences · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Evaluation ofMolecular biology research communications · 2024
    Article
  7. Review
  8. A Feedback Loop between TGF-β1 andCurrent issues in molecular biology · 2023
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Energy and caloric restriction, and fasting and cancer: a narrative review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Review
  19. Article
  20. Article

96 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ning ChenUniversity of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA.
Vassiliki Karantza

Funding

Role of Autophagy in Breast CancerR00CA133181 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI KARANTZA, VASSILIKI · 2009 to 2011
$734k
NCI NIH HHS R00 CA133181
6 · The paper itself

Abstract

Autophagy is a self-catabolic process that maintains intracellular homeostasis and prolongs cell survival under stress via lysosomal degradation of cytoplasmic constituents and recycling of amino acids and energy. Autophagy is intricately involved in many aspects of human health and disease, including cancer. Autophagy is a double-edged sword in tumorigenesis, acting both as a tumor suppressor and a protector of cancer cell survival, and elucidation of its exact role at different stages of cancer progression and in treatment responsiveness is a complex and challenging task. Better understanding of autophagy regulation and its impact on treatment outcome will potentially allow us to identify novel therapeutic targets in cancer. In this review, we summarize current knowledge on the regulation and dual function of autophagy in tumorigenesis, as well as ongoing efforts in modulating autophagy for cancer treatment and prevention. This is a very exciting and highly promising area of cancer research, as pharmacologic modulation of autophagy appears to augment the efficacy of currently available anticancer regimens and opens the way to the development of new combinatorial therapeutic strategies that will hopefully contribute to cancer eradication.

Indexed as

AutophagyCell SurvivalClinical Trials as TopicCytoplasmGenes, Tumor SuppressorHumansNeoplasms

Identifiers

PMID21228626
PMCPMC3230307

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.